News

Canada-based ConjuChem Biotechnologies, which is engaged in the discovery of therapeutics with an initial focus on diabetes, has reported a net loss of $5.83m, or $0.02 per share,

Intravascular ultrasound technology enables physicians to see detailed images inside the heart and coronary arteries. The company said the iCross catheter would be available immediately in the US.

The lawsuits are based on abbreviated new drug applications (ANDA) filed by Teva and Mylan seeking permission to manufacture and market a generic version of Tarceva before the

Biolase Technology, a dental laser company, has reported a net loss of $5.29m, or $0.22 per share, for the fourth quarter of 2008, compared to a net loss

Prior to joining Alvine Pharmaceuticals, Dr Adelman was senior vice president of development and chief medical officer at Sunesis Pharmaceuticals. Prior to that, Dr Adelman served in various

Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a treatment for adult patients with major depressive disorder. As

The cooperative R&D agreement with Maxim Biotech will initially focus on the development of a family of life science research reagent tool kits which can be used to

The company has also announced that William Rueckert has resigned from its board, and has accepted a position on the board of the company’s 72% shareholder, Novogen. Ms

Previously, Dr Emerson has served as director of computer resources at KPMG in its New York executive office; vice president of technology at Pansophic Systems; president of RTI